NCI Launches Randomized Trial of Shark Cartilage in NSCLC

Article

BETHESDA, Md-Enrollment has begun in a trial of Neovastat (Aeterna Laboratories), also known as AE-941, to test the Canadian-produced shark cartilage extract in patients with unresectable stages IIIA and IIIB non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy and radiation therapy.

BETHESDA, Md—Enrollment has begun in a trial of Neovastat (Aeterna Laboratories), also known as AE-941, to test the Canadian-produced shark cartilage extract in patients with unresectable stages IIIA and IIIB non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy and radiation therapy.

The randomized, double-blind, placebo-controlled study, supported by the National Cancer Institute, anticipates enrolling 756 patients within the next 3 years at more than 50 sites in the United States and Canada.

Recent Videos
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – January 10, 2025

CGTLive Staff
January 10th 2025
Article

Review top news and interview highlights from the week ending January 10, 2025.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

Tenaya’s Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data

Tenaya’s Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data

Noah Stansfield
January 9th 2025
Article

The data comes from 3 patients treated at the trial’s low dose.

Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona

The Promise of Cell Therapy Approaches in Epilepsy

Marco Meglio
December 17th 2024
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Jonathan Parker, MD, PhD.

RESTEM’s ULSC Therapy Restem-L Fast Tracked by FDA for Idiopathic Inflammatory Myopathy

RESTEM’s ULSC Therapy Restem-L Fast Tracked by FDA for Idiopathic Inflammatory Myopathy

Noah Stansfield
January 7th 2025
Article

Restem-L previously received orphan drug designation from the FDA for PM/DM in December 2024.

Heather Lau, MD, MS

Ultragenyx Puts BLA for MPSIII Gene Therapy UX111 in Front of FDA

Noah Stansfield
January 7th 2025
Article

Ultragenyx is seeking accelerated approval for the BLA based on the use of CSF heparan sulfate data from the phase 1/2/3 Transpher A clinical trial.

© 2025 MJH Life Sciences

All rights reserved.